A new strategy for delivering bulky PROTACs to cancerous cells successfully utilizes the CD36 protein pathway on cells’ surfaces.

This dramatically improves the uptake of a promising class of cancer-fighting drugs called PROTACs. The new drug design deliveries up to 22 times more of he drug inside cancer cells, and tumor ...

The strategy was particularly successful for a class of complex, large-sized drugs known as bRo5 molecules, such as PROTACs, a type of targeted cancer therapy that breaks down proteins in cells.

Scientists at Duke University School of Medicine, University of Texas Health Science Center at San Antonio, and University of Arkansas have found a way to improve the uptake of a promising class of ...

Breakthrough research could make any IV drug able to be taken orally for a range of hard-to-treat cancers and other diseases, and redefine how medicines are designed, evaluated and delivered. A ...

The paper underscores the potential of PROTACs to address unmet needs in crop resilience, productivity, and sustainability — with the precision and adaptability that modern agriculture demands.

The paper underscores the potential of PROTACs to address unmet needs in crop resilience, productivity, and sustainability — with the precision and adaptability that modern agriculture demands. This ...

Biocartis announced the launch of its real-time quantitative polymerase chain reaction assay to detect POLE and POLD1 mutations in endometrial cancer. Biocartis has launched a fully automated, ...